From the Journals

Menstrual irregularity appears to be predictor of early death


 

FROM THE BMJ

Expert suggests a probable underlying link

Dr. Reshef Tal

Dr. Reshef Tal

“Irregular menstrual cycles in women have long been known to be associated with significant morbidities, including the leading causes of mortality worldwide such as cardiovascular disease and cancer,” Reshef Tal, MD, PhD, assistant professor of obstetrics, gynecology & reproductive sciences at Yale University, New Haven, Conn., said in an interview. “The findings of this large study that irregular menstrual cycles are associated with premature death, most strongly from cardiovascular causes, are therefore not surprising.”

Dr. Tal acknowledged that one probable underlying link is PCOS, which is recognized as the most common hormonal disorder affecting women of reproductive age. The irregular periods that characterize PCOS are tied to a number of metabolic risk factors, including obesity, insulin resistance, dyslipidemia, and hypertension, which increase the long-term risk of cardiovascular disease and cancer of the uterus.

“The study did not have information on patients’ pelvic ultrasound findings and male hormone levels, which would have helped to establish PCOS diagnosis. However, women in this study who had irregular cycles tended to have more hirsutism, high cholesterol, hypertension as well as higher BMI, suggesting that PCOS is at least partly responsible for the observed association with cardiovascular disease. Interestingly, the association between irregular cycles and early mortality was independent of BMI, indicating that mechanisms other than metabolic factors may also play a role,” observed Dr. Tal, who was asked to comment on the study.

“Irregular periods are a symptom and not a disease, so it is important to identify underlying metabolic risk factors. Furthermore, physicians are advised to counsel patients experiencing menstrual irregularity, [to advise them to] maintain a healthy lifestyle and be alert to health changes,” Dr. Tal suggested.

The study was funded by the National Institutes of Health. The investigators had no relevant financial disclosures. Dr. Tal said he had no relevant financial disclosures.

SOURCE: Chavarro J et al. BMJ. 2020. doi: 10.1136/bmj.m3464.

Pages

Recommended Reading

Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
MDedge Internal Medicine
Should all patients with advanced ovarian cancer receive frontline maintenance therapy?
MDedge Internal Medicine
FDA approves medication to treat heavy menstrual bleeding related to fibroids
MDedge Internal Medicine
Pubovaginal sling during urethral diverticulectomy reduces stress incontinence
MDedge Internal Medicine
FDA allows qualified claims for UTI risk reduction with cranberry products
MDedge Internal Medicine
Treating VIN while preventing recurrence
MDedge Internal Medicine
Appendix may be common site of endometriosis
MDedge Internal Medicine
New nonhormonal hot flash treatments on the way
MDedge Internal Medicine
Fetal estrogens show promise for safer therapy for menopause
MDedge Internal Medicine
PCOS tied to risk for cardiovascular disease after menopause
MDedge Internal Medicine